Viewing Study NCT06984328

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:32 AM
Ignite Modification Date: 2026-04-11 @ 11:53 AM
Study NCT ID: NCT06984328
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-02
First Post: 2025-05-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Sponsor: Genmab
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Cutaneous Melanoma (Stage IV) View
None Cutaneous Melanoma View
None Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Melanoma View
None Cutaneous Melanoma View
None Metastatic Melanoma View